Document Detail


Increased risk of rebleeding of peptic ulcer bleeding in patients with comorbid illness receiving omeprazole infusion.
MedLine Citation:
PMID:  14696515     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND/AIMS: The study aimed to evaluate whether administration of intravenous omeprazole has different rebleeding rates for peptic ulcer bleeding of patients with and without comorbid illness. METHODOLOGY: A total of 80 patients with peptic ulcer bleeding were enrolled after therapeutic endoscopy to achieve hemostasis. Each patient had received omeprazole 80 mg bolus loading and 40 mg twice daily for three days (total dosage of 320 mg within 3 days). Two subgroups were divided, based on the absence (Group A) or presence (Group B) of one or more comorbid illnesses, such as chronic obstructive pulmonary disease, congestive heart failure, uremia, cirrhosis, diabetes mellitus, and old stroke. The 7-day and 28-day rebleeding rates were recorded. RESULTS: The presence of comorbid illness had a higher rebleeding rate than those without comorbid illness (7-day: 32.5 vs. 2.5%, p < 0.05; 28-day: 37.5 vs. 5.0%, p < 0.05). Patients with two or more comorbid diseases had an even higher risk of rebleeding than those with a single comorbid illness (66.7% vs. 26.5%, p < 0.05). CONCLUSIONS: Low-dose infusion of omeprazole can achieve favorable control of rebleeding in the patients with peptic ulcer bleeding but without comorbid diseases. As patients with comorbid illness had a higher risk of rebleeding, a higher dosage or prolonged duration of omeprazole infusion would be rationally indicated to prevent risk of rebleeding.
Authors:
Hsiu-Chi Cheng; Sam-An Chuang; Ya-Huey Kao; Ai-Wen Kao; Chiao-Hsiung Chuang; Bor-Shyang Sheu
Related Documents :
2445155 - Fungal infections occurring under bandages in leg ulcer patients.
22347675 - Early microsurgical treatment for spinal hemangioblastomas improves outcome in patients...
23713495 - Amyloid fibrils containing fragmented attr may be the standard fibril composition in at...
21439275 - Influence of diabetes on homocysteine-lowering therapy in chronic hemodialysis patients.
10365905 - Carbohydrate 19-9 antigen as a marker of non-malignant hepatocytic ductular transformat...
21796555 - Gallbladder ascariasis.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Hepato-gastroenterology     Volume:  50     ISSN:  0172-6390     ISO Abbreviation:  Hepatogastroenterology     Publication Date:    2003 Nov-Dec
Date Detail:
Created Date:  2003-12-30     Completed Date:  2004-06-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8007849     Medline TA:  Hepatogastroenterology     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2270-3     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Institute of Clinical Medicine, National Cheng Kung University Hospital, 138, Sheng Li Road, Tainan, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anti-Ulcer Agents / administration & dosage*
Comorbidity
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Gastroscopy
Hemostatic Techniques
Humans
Infusions, Intravenous
Liver Cirrhosis / epidemiology
Male
Middle Aged
Omeprazole / administration & dosage*
Peptic Ulcer Hemorrhage / drug therapy*,  epidemiology*
Pulmonary Disease, Chronic Obstructive / epidemiology
Recurrence / prevention & control
Risk Factors
Taiwan
Treatment Failure
Uremia / epidemiology
Chemical
Reg. No./Substance:
0/Anti-Ulcer Agents; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How to eradicate Helicobacter pylori using amoxicillin and omeprazole in the remnant stomach.
Next Document:  High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. p...